# OnCo record ezh2-y646-mutation (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/ezh2-y646-mutation/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "ezh2-y646-mutation" ;
  schema:name "EZH2 gain-of-function mutation (Tyr646, originally Tyr641)"@en ;
  schema:alternateName "EZH2 Y646"@en, "EZH2 Y641"@en, "EZH2 mutation"@en, "EZH2 Tyr641"@en, "EZH2-mutant follicular lymphoma"@en ;
  schema:description "A change in an enzyme that puts a chemical silencing mark on DNA. The altered enzyme adds too much of the mark, which keeps a lymphoma cell locked in the state it should have grown out of. It is the one lymphoma mutation that currently selects a tablet."@en ;
  schema:url <https://onco.cc/biomarkers/ezh2-y646-mutation/> ;
  schema:dateModified "2026-09-30"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/ng.518>, <https://doi.org/10.1056/NEJMoa1801445> ;
  onco:tag "biomarker", "lymphoma" ;
  onco:related <https://onco.cc/biomarkers/bcl2-rearrangement/> ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/bcl2/> ;
  onco:drugs <https://onco.cc/drugs/tazemetostat/> ;
  onco:pathways <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/germinal-centre-reaction/> ;
  onco:terms <https://onco.cc/terms/lymphoma-bio-germinal-centre/>, <https://onco.cc/terms/lymphoma-bio-lymphgen/>, <https://onco.cc/terms/flipi/>, <https://onco.cc/terms/ngs/> .